Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis.
Colorectal
Lung
Metastases
Overall survival
Progression-free survival
Radiofrequency ablation
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
05
2020
accepted:
05
08
2020
pubmed:
20
8
2020
medline:
7
4
2021
entrez:
20
8
2020
Statut:
ppublish
Résumé
To evaluate the long-term outcome of image-guided radiofrequency ablation (RFA) when treating histologically confirmed colorectal lung metastasis in terms of overall survival (OS), progression-free survival (PFS) and local tumour control (LTC). Retrospective single-centre study. Consecutive RFA treatments of histologically proven lung colorectal metastases between 01/01/2008 and 31/12/14. The primary outcome was patient survival (OS and PFS). Secondary outcomes were local tumour progression (LTP) and complications. Prognostic factors associated with OS/ PFS were determined by univariate and multivariate analyses. Sixty patients (39 males: 21 females; median age 69 years) and 125 colorectal lung metastases were treated. Eighty percent (n = 48) also underwent lung surgery for lung metastases. Mean metastasis size (cm) was 1.4 ± 0.6 (range 0.3-4.0). Median number of RFA sessions was 1 (1-4). During follow-up (median 45.5 months), 45 patients died (75%). The estimated OS and PFS survival rates at 1, 3, 5, 7, 9 years were 96.7%, 74.7%, 44.1%, 27.5%, 16.3% (median OS, 52 months) and 66.7%, 31.2%, 25.9%, 21.2% and 5.9% (median PFS, 19 months). The LTC rate was 90% with 6 patients developing LTP with 1-, 2-, 3- and 4-year LTP rates of 3.3%, 8.3%, 10.0% and 10.0%. Progression-free interval < 1 year (P = 0.002, HR = 0.375) and total number of pulmonary metastases (≥ 3) treated (P = 0.037, HR = 0.480) were independent negative prognostic factors. Thirty-day mortality rate was 0% with no intra-procedural deaths. The long-term OS and PFS following RFA for the treatment of histologically confirmed colorectal lung metastases demonstrate comparable oncological durability to surgery.
Identifiants
pubmed: 32812121
doi: 10.1007/s00270-020-02623-1
pii: 10.1007/s00270-020-02623-1
pmc: PMC7649179
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1900-1907Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018;68:394–424.
Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg [Internet]. 2006;93(1):1115–22.
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut [Internet]. 2010;59:1383–8.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol [Internet]. 2016;27(8):1386–422.
Venturini M, Cariati M, Marra P, Masala S, Pereira P, Carrafiello G. CIRSE standards of practice on thermal ablation of primary and secondary lung tumours. Cardiovasc Intervent Radiol. 2020;43(5):667–83.
pubmed: 32095842
Yuan Z, Wang Y, Zhang J, Zheng J, Li W. A meta-analysis of clinical outcomes after radiofrequency ablation and microwave ablation for lung cancer and pulmonary metastases. J Am Coll Radiol [Internet]. 2019;16(3):302–14.
De BT, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases : experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26:987–91.
De BT, Tselikas L, Gravel G, Deschamps F. Lung ablation : best practice/results/response assessment/role alongside other ablative therapies. Clin Radiol. 2017;72(8):657–64.
Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thorac Cancer [Internet]. 2018;9(2):199–207.
Schlijper RCJ, Grutters JPC, Houben R, Dingemans AMC, Wildberger JE, Van RD, et al. What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? Cancer Treat Rev [Internet]. 2014;40:60–7.
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria—A 10-year update. Radiology [Internet]. 2014;273(1):241–60.
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol [Internet]. 2017;40:1141–6.
Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology [Internet]. 2008;246(3):697–772.
Yamakado K, Hase S, Matsuoka T, Tanigawa N, Nakatsuka A, Takaki H, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol [Internet]. 2007;18(3):393–8.
Matsui Y, Hiraki T, Gobara H, Iguchi T, Fujiwara H, Nagasaka T, et al. Long-term survival following percutaneous radiofrequency ablation of colorectal lung metastases. J Vasc Interv Radiol [Internet]. 2015;26:303–10.
Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Kanazawa S. Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol. 2014;20(4):988–96.
pubmed: 3921550
pmcid: 3921550
Gillams A, Khan Z, Osborn P, Lees W. Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol [Internet]. 2013;36:724–30.
Fanucchi O, Ambrogi MC, Aprile V, Cioni R, Cappelli C, Melfi F, et al. Long-term results of percutaneous radiofrequency ablation of pulmonary metastases: a single institution experience. Interact Cardiovasc Thorac Surg. 2016;23(1):57–64.
pubmed: 4986752
pmcid: 4986752
Tselikas L, de Baere T, Deschamps F, Hakimé A, Besse B, Teriitehau C, et al. Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. Eur Radiol [Internet]. 2017;27:1211–7.
Lyons NJR, Pathak S, Daniels IR, Spiers A, Smart NJ. Percutaneous management of pulmonary metastases arising from colorectal cancer: a systematic review. Eur J Surg Oncol [Internet]. 2015;41:1447–555.
Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol [Internet]. 2009;27:3677–83.
Vogl TJ, Eckert R, Naguib NNN, Beeres M, Gruber-Rouh T, Nour-Eldin NEA. Thermal ablation of colorectal lung metastases: retrospective comparison among laser-induced thermotherapy, radiofrequency ablation, and microwave ablation. Am J Roentgenol [Internet]. 2016;207:1340–9.
Petre EN, Jia X, Thornton RH, Sofocleous CT, Alago W, Kemeny NE, et al. Treatment of pulmonary colorectal metastases by radiofrequency ablation. Clin Colorectal Cancer [Internet]. 2013;12(1):37–44.
Blackmon SH, Stephens EH, Correa AM, Hofstetter W, Kim MP, Mehran RJ, et al. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg [Internet]. 2012;94:1802–9.
Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg [Internet]. 2004;91(1):112–20.
Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol [Internet]. 2006;13(11):1538–44.
Welter S, Jacobs J, Krbek T, Poettgen C, Stamatis G. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardio-thoracic Surg [Internet]. 2007;31(2):167–72.
Onaitis MW, Petersen RP, Haney JC, Saltz L, Park B, Flores R, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg [Internet]. 2009;87:1684–8.
Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg [Internet]. 2013;257:1059–64.
Hirosawa T, Itabashi M, Ohnuki T, Yamaguchi N, Sugihara K, Kameoka S. Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today [Internet]. 2013;43:494–9.
Bölükbas S, Sponholz S, Kudelin N, Eberlein M, Schirren J. Risk factors for lymph node metastases and prognosticators of survival in patients undergoing pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg [Internet]. 2014;97(6):1926–32.
Sun F, Chen L, Shi M, Yang X, Li M, Yang X, et al. Prognosis of video-assisted thoracoscopic pulmonary metastasectomy in patients with colorectal cancer lung metastases: an analysis of 154 cases. Int J Colorectal Dis [Internet]. 2017;32:897–905.
Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, et al. Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg [Internet]. 2017;104(3):979–87.
Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology [Internet]. 2007;243:268–75.
Ferguson J, Alzahrani N, Zhao J, Glenn D, Power M, Liauw W, et al. Long term results of RFA to lung metastases from colorectal cancer in 157 patients. Eur J Surg Oncol [Internet]. 2015;41:690–5.
Shi F, Li G, Zhou Z, Xu R, Li W, Zhuang W, et al. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. Oncotarget [Internet]. 2017;8(65):109791–8.
Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol [Internet]. 2013;20:572–9.
Lubner MG, Brace CL, Hinshaw JL, Lee FT. Microwave tumor ablation: Mechanism of action, clinical results, and devices. J Vasc Interv Radiol [Internet]. 2010;21(8):S192–203.
Wolf FJ, Grand DJ, Machan JT, DiPetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology [Internet]. 2008;247(3):871–9.
Lu Q, Cao W, Huang L, Wan Y, Liu T, Cheng Q, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: results in 69 cases. World J Surg Oncol [Internet]. 2012;10:80.
Macchi M, Belfiore MP, Floridi C, Serra N, Belfiore G, Carmignani L, et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. Med Oncol [Internet]. 2017;34:96.
Soomro N, Lecouturier J, Stocken DD, Shen J, Hynes AM, Ainsworth HF, et al. Surveillance versus ablation for incidentally diagnosed small renal tumours: The SURAB feasibility RCT. Health Technol Assess [Internet]. 2017;21(81):1–68.
ClinicalTrials.gov [Internet]. Identifier: NCT01608165—A feasibility study for a multicentre randomised controlled trial to compare surgery with needle ablation techniques in people with small renal masses (4cm) (CONSERVE). 2012.
Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20(1):718.
pubmed: 31831062
pmcid: 6909580
Yamakado K, Inoue Y, Takao M, Takaki H, Nakatsuka A, Uraki J. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep. 2009;22(4):885–9.
pubmed: 19724869